ACE-031 is a recombinant fusion protein that combines the extracellular domain of the human activin receptor type IIB (ActRIIB) with the Fc fragment of human immunoglobulin G1 (IgG1). In scientific research, it is studied as a model compound and as a soluble ligand decoy receptor in the signaling of the TGF-\u03b2 superfamily. The compound is offered as a freeze-dried powder (lyophilized powder) and is intended exclusively for laboratory and research purposes.<\/p>\n
ACE-031, also referred to by the synonym Ramatercept, belongs to the class of recombinant ActRIIB-Fc fusion proteins. It consists of the ligand-binding, extracellular part of the activin receptor type IIB, which is fused to the Fc domain of human IgG1 via a defined coupling. In research models, the Fc part provides dimerization of the structure and increased molecular stability, making the protein a useful tool for studying receptor-ligand interactions in controlled systems.<\/p>\n
The endogenous ActRIIB receptor normally binds multiple signaling factors from the TGF-\u03b2 superfamily, including myostatin (GDF-8), activin A and B, GDF-11, and several bone morphogenetic proteins (BMPs). As a soluble derivative of that receptor domain, ACE-031 acts as a competitive ligand scavenger in research: it binds these factors in solution before they can reach the receptor on the cell surface. In this way, the subsequent intracellular SMAD signaling pathway is modulated, making ACE-031 a widely used model compound in the study of this signal cascade.<\/p>\n
ACE-031 acts on the inhibitory axis of the TGF-\u03b2 superfamily and thereby differs fundamentally from compounds that act on the growth hormone and IGF-1 axes. Whereas ACE-031 sequesters ligands as a soluble receptor, growth hormone secretagogues such as Ipamorelin 10mg<\/a> and GHRH analogues such as Tesamorelin<\/a> specifically the release of endogenous growth hormone via their own receptors. Researchers mapping the IGF-1 axis also often place ACE-031 next to IGF-1 LR3 1 mg<\/a> and the IGF-1-related fragment MGF 2mg<\/a>These compounds are used in laboratory research to study various, complementary signaling pathways regarding tissue homeostasis side by side; ACE-031 represents the decoy-receptor approach in this context.<\/p>\nSpecifications<\/h2>\n
| Specification<\/th>\n | Value<\/th>\n<\/tr>\n<\/thead>\n |
|---|---|
| Sample<\/td>\n | ACE-031 (ActRIIB-Fc)<\/td>\n<\/tr>\n |
| Synonyms<\/td>\n | Ramatercept, ActRIIB-Fc<\/td>\n<\/tr>\n |
| Class<\/td>\n | Recombinant fusion protein (ActRIIB extracellular domain + human IgG1-Fc fragment)<\/td>\n<\/tr>\n |
| Form<\/td>\n | Freeze-dried powder (lyophilisate), 1 mg per vial<\/td>\n<\/tr>\n |
| Purity<\/td>\n | \u2265 99% (HPLC)<\/td>\n<\/tr>\n |
| Storage<\/td>\n | Store refrigerated or at -20 \u00b0C, protected from light and moisture.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Because ACE-031 is a recombinant, glycosylated fusion protein and not a classical small molecule or short peptide, a single CAS number, a molecular formula, and a PubChem CID are deliberately omitted here: for this protein class, those values \u200b\u200bcannot be determined unambiguously and reliably. The table is therefore limited to the data that can be accurately confirmed.<\/p>\n Shape, handling and storage<\/h2>\nACE-031 is supplied as a freeze-dried powder in a 1 mg vial. As a protein, the compound is more sensitive to mechanical and thermal stress than short synthetic peptides. When reconstituting in a laboratory context, the appropriate solvent is carefully added along the wall of the vial; vigorous shaking and repeated freeze-thaw cycles are avoided to maintain structural integrity. Store the freeze-dried product refrigerated or at -20 \u00b0C, protected from light and moisture; after reconstitution, the reconstituted material is kept refrigerated (2\u20138 \u00b0C). All handling takes place exclusively within a research and laboratory setting.<\/p>\n Purity and lab results<\/h2>\n |